Glaukos announced positive results from a trial evaluating the safety of the surgical exchange procedure for its iDose TR (travoprost intraocular implant) for glaucoma.
The ophthalmic medical technology and pharmaceutical company – focused on novel therapies for glaucoma, corneal disorders and retinal diseases – revealed results of the multi-centre trial in subjects who had previously been administered an iDose TR in the Phase 2b clinical trial (referred to as the ‘exchange trial’).
Results from the exchange trial demonstrated a second administration of iDose TR and removal of the original iDose TR implant was safe and well-tolerated, with the second iDose TR demonstrating a favourable safety profile over a 12-month evaluation period.
Additionally, Glaukos reported that no subject in the exchange trial exhibited a greater than 30% endothelial cell loss over the extended evaluation period of more than five years on average.
Glaukos now plans to include the exchange trial’s positive data set in its upcoming US Food and Drug Administration (FDA) New Drug Application (NDA) submission targeted for the first quarter of 2023.
“We are pleased to clinically confirm the iDoseTR exchange procedure is safe and facile. We look forward to including these positive data in our upcoming NDA submission to further support the safety and tolerability of redosing iDose TR patients over time,” Mr Thomas Burns, Glaukos chairman and CEO, said.
“We continue to believe iDose TR can be a transformative novel technology able to fundamentally improve the treatment paradigm for patients with glaucoma.”
The exchange trial, based upon an agreement with the FDA, was designed to evaluate the feasibility and safety of a surgical exchange procedure of iDose TR in subjects who were previously implanted with iDose TR as part of the iDose TR Phase 2b clinical trial.
A total of 33 people were enrolled and 32 (97.0%) completed the trial. The average time from administration of the first implant (first implantation cycle) in the Phase 2b trial to the time of the exchange procedure of the second implant in the exchange trial (second implantation cycle) was 4.2 years.
The exchange trial subjects were then followed for an additional year following the second implantation cycle, for an overall extended evaluation period average of 5.2 years.
During the exchange procedure using the pre-loaded injector, the surgeon inserted and anchored the new implant into the sclera at least one clock hour away from the previous implant from the first implantation cycle, and using the now-empty inserter, grasped and removed the previous implant.
Administered during a micro-invasive procedure, the iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is designed to be removed and replaced with a new iDose TR, thus potentially offering a dropless alternative to daily eye drop treatment.
More reading
Glaukos announces FDA clearance for iStent infinite
Glaukos commences trials for its third-generation keratoconus therapy
Glaukos trials eyelid cream to treat presbyopia and dry eye
